New Mexico 2025 Regular Session

New Mexico House Bill HB236

Caption

Notice For Medication Abortions

Impact

This bill imposes new obligations on medical providers by requiring them to post signs related to medication abortions and to provide specific information to patients 24 hours prior to the abortion procedure. Facilities that fail to comply may face fines up to $10,000. While supporters argue that this empowers patients and enhances care, critics contend that it may create additional barriers for individuals seeking abortions, particularly in non-emergency cases.

Summary

House Bill 236, introduced by Representative Jenifer Jones, aims to regulate the provision of medication abortions, specifically those involving the drug mifepristone. The bill mandates that healthcare facilities, including clinics, hospitals, and pharmacies, provide explicit notices to patients seeking medication abortions. The notice informs patients that mifepristone is not always effective and outlines potential options for reversing its intended effects if the second pill has not been taken. This requirement sets a standard for patient information aimed at promoting awareness and informed decisions.

Contention

Notably, the bill includes provisions that allow for civil actions against physicians who do not comply with the notification requirements. Critics of HB236 argue that such legal implications may deter doctors from providing necessary care or may lead to inadvertent lawsuits, thereby impacting patient access to services. Furthermore, the definition of 'medical emergency' used in the bill excludes psychological or emotional conditions, raising concerns about the limitations imposed on patients' rights to make decisions about their health care.

Companion Bills

No companion bills found.

Similar Bills

CA SB1428

Reproductive health: mifepristone and other medication.

CA AB54

Access to Safe Abortion Care Act.

US HR1285

Condemning the pro-abortion policies of the Biden administration.

US SR510

A resolution expressing the sense of the Senate that the scientific judgement of the Food and Drug Administration that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable and based on science.

NJ SR78

Urges United States Supreme Court to protect freedom of reproductive choice with respect to use of and access to mifepristone.

NJ AR190

Urges United States Supreme Court to protect freedom of reproductive choice with respect to use of and access to mifepristone.

HI HB866

Relating To Health Care.

HI SB1246

Relating To Health Care.